Timothée Olivier, MD

2.5K posts

Timothée Olivier, MD banner
Timothée Olivier, MD

Timothée Olivier, MD

@Timothee_MD

Oncology (sarcoma, H&N, CUP). EBM, Health Policy @HUG_ge (Geneva), @vkprasadlab (UCSF). Geneva Ethics Committee. Co-EiC ESMO Rare Cancers. No COI. Views mine.

Genève, Suisse Katılım Aralık 2021
418 Takip Edilen2.9K Takipçiler
Timothée Olivier, MD retweetledi
Papa Heme
Papa Heme@Papa_Heme·
Everyone should read this before treating smoldering myeloma. Evolving challenges in smoldering myeloma trials: shifting endpoint measurement and definitions - ScienceDirect sciencedirect.com/science/articl…
English
0
6
36
4.3K
Timothée Olivier, MD
Timothée Olivier, MD@Timothee_MD·
Our new article is out in EJC with Sahar van Waalwijk and David Thomas! Reimbursement decisions may be less strongly backed by clinical evidence and more driven by the unmet needs, e.g. reimbursement in childhood cancers where the data are only available for adults. However, this is unprecedented in any public healthcare:  In Australia, the PBAC is reimbursing ipilimumab plus nivolumab for tumour‑agnostic use, even though the DART trial showed an overall response rate of only 12%, with significant toxicities. Read why we believe such a reimbursement decision is unwarranted, and what alternatives we propose. theoncologyshot.com/p/world-first-…
Timothée Olivier, MD tweet media
English
0
1
11
982
Timothée Olivier, MD
Timothée Olivier, MD@Timothee_MD·
Congrats for the amazing work you did at the @US_FDA Tracy, you are an outsanding researcher and leader. I'm sure your will contribute to even greater achievements for patients and the society in the future. @TracyBethHoeg : “Marty and I, and Vinay as well, I think we all leave holding our heads high because we refused to bow to political pressure and to pressure from lobbyists to do things in order to keep our jobs or protect our reputations.”
Tracy Beth Høeg, MD, PhD@TracyBethHoeg

Today marked 6 months as head of CDER at @FDA & today I was fired I’m incredibly grateful to have had this opportunity to serve this country & proud of the work we did FDA staff are smart, talented, supportive & don’t get enough credit I learned so much & leave with no regrets

English
3
3
23
4.5K
Timothée Olivier, MD retweetledi
Alfredo Addeo MD
Alfredo Addeo MD@Alfdoc2·
Great exchange of ideas at #ESMOInFocus Lung Cancer Romania 🇷🇴.Honored to participate in this excellent meeting focused on the evolving landscape of thoracic oncology.Pleased to share the stage with outstanding colleagues @gbanna74 @MARIANOPROVENCI #ESMOInFocus
Alfredo Addeo MD tweet mediaAlfredo Addeo MD tweet mediaAlfredo Addeo MD tweet mediaAlfredo Addeo MD tweet media
English
1
4
13
871
Timothée Olivier, MD retweetledi
Papa Heme
Papa Heme@Papa_Heme·
Academic oncology has gotten bad. Many are scared to share their true opinions on matters as leaders in the field will black ball them. True innovation thrives on diversity in view points.
English
13
20
170
18.9K
Timothée Olivier, MD retweetledi
Papa Heme
Papa Heme@Papa_Heme·
I know running clinical trials is tough but that doesn’t mean us clinicians have to accept the results as the new standard if we find the results not applicable to our current practice.
English
8
13
106
10.5K
Timothée Olivier, MD retweetledi
Alfredo Addeo MD
Alfredo Addeo MD@Alfdoc2·
@TracyBethHoeg @Timothee_MD Definitely brilliant, smart and hilarious.Totally bummed he had left FDA I admire the courage to stand his ground. In society where being a yes-men is convenient I can only have respect and admiration for someone like him who chooses to follow and defend his principles
English
0
1
14
617
Timothée Olivier, MD retweetledi
Bernie Marini
Bernie Marini@Berninini·
Young clinicians don’t need to make critical appraisal their primary academic focus, but it is a skill every clinician MUST learn as early as possible. No trial is perfect but understanding the implications of imperfections is 🔑. And remember - critique trials, not people!
Vincent Rajkumar@VincentRK

I know some have become experts at clinical appraisal and clinical trial critique. It’s important to have this dialogue and it helps physicians and patients understand the drawbacks of a given trial. But my advise to young investigators is to best not to make it your primary academic output. Secondly, when critiquing it’s also worthwhile remembering that the investigators of trials may also fully aware of the issues but there are many barriers and often we have to choose between not doing a trial at all versus compromising. Perfect trials are not common; we can usually find some fault with almost all trials. So we must strive to avoid rudeness and condescension. Third, try if possible to lead a clinical trial or at least get engaged with someone who leads trials and get a feel for the various stakeholders who have veto power during trial design, and more importantly the various competing priorities for what the trial seeks to accomplish, it will be easier to understand why a specific control arm was chosen, or a why a specific endpoint was chosen, even though you may think they are the wrong ones.

English
2
8
37
4.4K
Timothée Olivier, MD retweetledi
Tracy Beth Høeg, MD, PhD
Tracy Beth Høeg, MD, PhD@TracyBethHoeg·
Thursday was Vinay's last official day at the FDA I'm very grateful I had another chance to work w him over the last year He is brilliant, hilarious, creative & did transformational work at the FDA Thanks to him for his service I look forward to following his future work ☀️
Tracy Beth Høeg, MD, PhD tweet media
English
44
14
230
19.1K
Clark Henegan
Clark Henegan@ClarkHenegan·
@katy_beckermann How tough was capivasertib? Based on these KM curves 27 patients in that arm may have been censored in the first 3 month and none in the control arm. Early censoring likely reflects toxicity @VPrasadMDMPH @Timothee_MD
Clark Henegan tweet media
English
1
0
1
177
Katy Beckermann
Katy Beckermann@katy_beckermann·
ODAC voted 7-1-1 today in favor of capivasertib + abiraterone for PTEN-deficient mHSPC. The vote came despite a negative immature OS readout, which is the real story. CAPItello-281 (n=1012): 🎯 PTEN-deficient mHSPC, biomarker-selected 📈 rPFS 33.2 vs 25.7 mo, HR 0.81, P=0.034 ❓ OS HR 0.90, P=0.40 (immature, 26.4% maturity) ⚠️ Serious AEs 42.5% vs 26.0% Worth watching how the FDA responds and how they label the indication, including which companion PTEN assay is required. Adoption in clinic will hinge on testing access and proactive AE management as much as the label itself. 📄 bit.ly/4t677aw #ProstateCancer #mHSPC #GUonc #ODAC #FOAMonc
Katy Beckermann tweet media
English
2
5
16
5.3K

Keşfet

@Nandinimenon18 @Alfdoc2 @NEJM @TracyBethHoeg @MartyMakary @VPrasadMDMPH @SecKennedy @AlecGaffney